
|Videos|May 14, 2019
Dr. Oratz on PARP Inhibitors to Treat Patients With Breast Cancer
Author(s)Ruth Oratz, MD
Cancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.
Advertisement
Cancer Network spoke with Ruth Oratz, MD, a medical oncologist and breast cancer specialist at NYU Langone Perlmutter Cancer Center in New York City, about the use of poly (ADP-ribose) polymerase inhibitors for patients diagnosed with breast cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Fast Track Designation to FG001 for High-Grade Glioma Surgery
2
Potential Rusfertide Approval May Offer More Control of Polycythemia Vera
3
FDA Approves Companion Diagnostic for Niraparib in Advanced Ovarian Cancer
4
NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
5
























































